FR2676231B1 - - Google Patents

Info

Publication number
FR2676231B1
FR2676231B1 FR9105572A FR9105572A FR2676231B1 FR 2676231 B1 FR2676231 B1 FR 2676231B1 FR 9105572 A FR9105572 A FR 9105572A FR 9105572 A FR9105572 A FR 9105572A FR 2676231 B1 FR2676231 B1 FR 2676231B1
Authority
FR
France
Prior art keywords
concentrate
factor
deficiency
chromatography
filtration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9105572A
Other languages
English (en)
French (fr)
Other versions
FR2676231A1 (fr
Inventor
Miryana-Nee-Radosevich Burnouf
Dominique Dernis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AETSRN
Original Assignee
AETSRN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AETSRN filed Critical AETSRN
Priority to FR9105572A priority Critical patent/FR2676231A1/fr
Priority to IL9956791A priority patent/IL99567A/en
Priority to DE69221369T priority patent/DE69221369T2/de
Priority to AT92401157T priority patent/ATE156360T1/de
Priority to DK92401157.0T priority patent/DK0512883T3/da
Priority to EP92401157A priority patent/EP0512883B1/fr
Priority to ES92401157T priority patent/ES2107511T3/es
Priority to AU15263/92A priority patent/AU652043B2/en
Priority to CA002068069A priority patent/CA2068069C/en
Priority to SU925011788A priority patent/RU2097047C1/ru
Priority to US07/879,273 priority patent/US5252217A/en
Priority to BR929201718A priority patent/BR9201718A/pt
Publication of FR2676231A1 publication Critical patent/FR2676231A1/fr
Priority to LTIP265A priority patent/LT3417B/lt
Priority to UA93002714A priority patent/UA27733C2/uk
Priority to EE9400003A priority patent/EE03017B1/xx
Application granted granted Critical
Publication of FR2676231B1 publication Critical patent/FR2676231B1/fr
Priority to GR970402766T priority patent/GR3025134T3/el
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6443—Coagulation factor XIa (3.4.21.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR9105572A 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation. Granted FR2676231A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR9105572A FR2676231A1 (fr) 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.
IL9956791A IL99567A (en) 1991-05-07 1991-09-25 Concentrate of high-activity blood clotting factor IX, suitable for drug use, and its preparation
DE69221369T DE69221369T2 (de) 1991-05-07 1992-04-23 Verfahren zur Herstellung eines Konzentrates von Blutgerinnungsfaktor XI mit hoher spezifischer Aktivität zur therapeutischen Verwendung
AT92401157T ATE156360T1 (de) 1991-05-07 1992-04-23 Verfahren zur herstellung eines konzentrates von blutgerinnungsfaktor xi mit hoher spezifischer aktivität zur therapeutischen verwendung
DK92401157.0T DK0512883T3 (da) 1991-05-07 1992-04-23 Fremgangsmåde til fremstilling af et koncentrat af blodkoaguleringsfaktor XI med høj specifik aktivitet, til terapeutisk anvendelse
EP92401157A EP0512883B1 (fr) 1991-05-07 1992-04-23 Procédé de préparation d'un concentré de facteur XI de la coagulation sanguine à haute activité spécifique, approprié à un usage thérapeutique
ES92401157T ES2107511T3 (es) 1991-05-07 1992-04-23 Procedimiento para la preparacion de un concentrado de factor xi de la coagulacion sanguinea con alta actividad especifica, apropiado para su uso terapeutico.
AU15263/92A AU652043B2 (en) 1991-05-07 1992-04-29 Blood coagulation factor X1 concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
CA002068069A CA2068069C (en) 1991-05-07 1992-05-06 Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
SU925011788A RU2097047C1 (ru) 1991-05-07 1992-05-06 Препарат человеческого фактора xi свертывания крови и способ его получения
US07/879,273 US5252217A (en) 1991-05-07 1992-05-07 Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
BR929201718A BR9201718A (pt) 1991-05-07 1992-05-07 Concentrado de fator xi da coagulacao sanguinea de alta atividade especifica,apropriado para uso terapeutico e seu processo de preparacao
LTIP265A LT3417B (en) 1991-05-07 1992-12-29 Blood coagulation factor xi concentrate and process for the preparing same
UA93002714A UA27733C2 (uk) 1991-05-07 1993-05-21 Препарат людського фактора хі згортання крові та спосіб його одержання
EE9400003A EE03017B1 (et) 1991-05-07 1994-05-23 Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks
GR970402766T GR3025134T3 (en) 1991-05-07 1997-10-22 Process for preparing a concentrate of blood coagulation factor XI with high specific activity, appropriate for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9105572A FR2676231A1 (fr) 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.

Publications (2)

Publication Number Publication Date
FR2676231A1 FR2676231A1 (fr) 1992-11-13
FR2676231B1 true FR2676231B1 (enExample) 1995-04-21

Family

ID=9412593

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9105572A Granted FR2676231A1 (fr) 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.

Country Status (16)

Country Link
US (1) US5252217A (enExample)
EP (1) EP0512883B1 (enExample)
AT (1) ATE156360T1 (enExample)
AU (1) AU652043B2 (enExample)
BR (1) BR9201718A (enExample)
CA (1) CA2068069C (enExample)
DE (1) DE69221369T2 (enExample)
DK (1) DK0512883T3 (enExample)
EE (1) EE03017B1 (enExample)
ES (1) ES2107511T3 (enExample)
FR (1) FR2676231A1 (enExample)
GR (1) GR3025134T3 (enExample)
IL (1) IL99567A (enExample)
LT (1) LT3417B (enExample)
RU (1) RU2097047C1 (enExample)
UA (1) UA27733C2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2151604C1 (ru) * 1999-01-21 2000-06-27 Станкевич Виктор Евгеньевич Способ приготовления универсальной гемотрансфузионной среды
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
JP2004534855A (ja) * 2001-07-20 2004-11-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび第ｘｉ因子ポリペプチドを含んでなる医薬組成物
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
RU2006115783A (ru) * 2003-11-20 2007-12-27 Ново Нордиск Хелс Кеа Аг (Ch) Терапевтическое применение фактора xi
WO2006128497A1 (en) * 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
US8350013B2 (en) * 2006-09-08 2013-01-08 Wyeth Llc Arginine wash in protein purification using affinity chromatography
ATE546520T1 (de) * 2007-01-04 2012-03-15 Crucell Holland Bv Faktor-xi-reinigung
KR101979134B1 (ko) 2008-10-15 2019-05-15 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
FR2974366B1 (fr) 2011-04-20 2016-06-24 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur xi
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
DE102012022233A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Verfahren zur Reinigung eines (Blut)plasmaproteins
DE102012022234A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Einstufiges Verfahren zur Reinigung von (Blut)Plasmaproteinen wie Albumin aus Gemischen
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
MY204000A (en) 2018-05-09 2024-07-31 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859340A (en) * 1976-03-15 1989-08-22 Cuno, Incorporated Filter sheet
US4783262A (en) * 1987-03-30 1988-11-08 Cuno Incorporated Separator for cell type filter element

Also Published As

Publication number Publication date
CA2068069A1 (en) 1992-11-08
EE03017B1 (et) 1997-08-15
BR9201718A (pt) 1992-12-29
FR2676231A1 (fr) 1992-11-13
AU1526392A (en) 1992-11-12
DE69221369D1 (de) 1997-09-11
DE69221369T2 (de) 1998-03-19
US5252217A (en) 1993-10-12
AU652043B2 (en) 1994-08-11
UA27733C2 (uk) 2000-10-16
CA2068069C (en) 2005-03-15
DK0512883T3 (da) 1998-03-16
GR3025134T3 (en) 1998-02-27
EP0512883B1 (fr) 1997-08-06
LT3417B (en) 1995-09-25
IL99567A (en) 1996-01-19
ATE156360T1 (de) 1997-08-15
EP0512883A1 (fr) 1992-11-11
LTIP265A (en) 1994-10-25
RU2097047C1 (ru) 1997-11-27
ES2107511T3 (es) 1997-12-01
IL99567A0 (en) 1992-08-18

Similar Documents

Publication Publication Date Title
FR2676231B1 (enExample)
EP0151910A3 (en) Radiotherapy treatment table
AU582972B2 (en) Lipoprotein adsorbent for use in extracorporeal circulation treatment and process for preparing thereof
AU588862B2 (en) Human tumor therapy
AU3133889A (en) Method for the treatment of the extraphyramidal side effects associated with neuroleptic therapy
AU576901B2 (en) Pain treatments in human joints
GB8319419D0 (en) Chair for body massage
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
EP0280593A3 (en) Composition on the basis of an amino-acid and vitamins for use in cancer therapy
ES8404693A1 (es) Procedimiento de preparacion de nuevos amino-14 esteroides.
EP0212310A3 (en) Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia
ZM10686A1 (en) New orth-anisamides process for their preparation and their therapeutic application
KR950013453B1 (en) Composition containing 15-deoxisper gualine
GR861655B (en) Preparation process for a medicine used for the psoriasis treatment and application therefor
ZA86101B (en) Process for recovering absorbent for use in extracorporeal circulation treatment
EP0199102A3 (en) Apparatus for the prophylaxis and therapy of spinal column disorders
ZA881828B (en) Preparation for treatment of skin disorders
AU99667S (en) Physical therapy treatment table
GB8613091D0 (en) Treatment tables
AU1704088A (en) Therapeutic treatment pad
HUT44429A (en) Therapeutic device for curing limb lesions particularly aortic stenosis
AU100486S (en) Therapy couch
KR900019957U (en) Bed for therapy
GB8912369D0 (en) Therapeutic turning bed
GB8721837D0 (en) Therapeutic foot massager

Legal Events

Date Code Title Description
ST Notification of lapse